Incidence of possible serious bacterial infection in young infants in the three high-burden countries of the Democratic Republic of the Congo, Kenya, and Nigeria: A secondary analysis of a large, multi-country, multi-centre clinical trial.
Journal
Journal of global health
ISSN: 2047-2986
Titre abrégé: J Glob Health
Pays: Scotland
ID NLM: 101578780
Informations de publication
Date de publication:
02 Feb 2024
02 Feb 2024
Historique:
medline:
2
2
2024
pubmed:
1
2
2024
entrez:
1
2
2024
Statut:
epublish
Résumé
Neonatal infections are a major public health concern worldwide, particularly in low- and middle-income countries, where most of the infection-related deaths in under-five children occur. Sub-Saharan Africa has the highest mortality rates, but there is a lack of data on the incidence of sepsis from this region, hindering efforts to improve child survival. We aimed to determine the incidence of possible serious bacterial infection (PSBI) in young infants in three high-burden countries in Africa. This is a secondary analysis of data from the African Neonatal Sepsis (AFRINEST) trial, conducted in the Democratic Republic of the Congo (DRC), Kenya, and Nigeria between 15 March 2012 and 15 July 2013. We recorded baseline characteristics, the incidence of PSBI (as defined by the World Health Organization), and the incidence of local infections among infants from 0-59 days after birth. We report descriptive statistics. The incidence of PSBI among 0-59-day-old infants across all three countries was 11.2% (95% confidence interval (CI) = 11.0-11.4). The DRC had the highest incidence of PSBI (19.0%; 95% CI = 18.2-19.8). Likewise, PSBI rates were higher in low birth weight infants (24.5%; 95% CI = 23.1-26.0) and infants born to mothers aged <20 years (14.1%; 95% CI = 13.4-14.8). The incidence of PSBI was higher among infants delivered at home (11.7%; 95% CI = 11.4-12.0). The high burden of PSBI among young infants in DRC, Kenya, and Nigeria demonstrates the importance of addressing PSBI in improving child survival in sub-Saharan Africa to reach the Sustainable Development Goals (SDGs). These data can support government authorities, policymakers, programme implementers, non-governmental organisations, and international partners in reducing preventable under-five deaths. Australian New Zealand Clinical Trials Registry: ACTRN12610000286044.
Sections du résumé
Background
UNASSIGNED
Neonatal infections are a major public health concern worldwide, particularly in low- and middle-income countries, where most of the infection-related deaths in under-five children occur. Sub-Saharan Africa has the highest mortality rates, but there is a lack of data on the incidence of sepsis from this region, hindering efforts to improve child survival. We aimed to determine the incidence of possible serious bacterial infection (PSBI) in young infants in three high-burden countries in Africa.
Methods
UNASSIGNED
This is a secondary analysis of data from the African Neonatal Sepsis (AFRINEST) trial, conducted in the Democratic Republic of the Congo (DRC), Kenya, and Nigeria between 15 March 2012 and 15 July 2013. We recorded baseline characteristics, the incidence of PSBI (as defined by the World Health Organization), and the incidence of local infections among infants from 0-59 days after birth. We report descriptive statistics.
Results
UNASSIGNED
The incidence of PSBI among 0-59-day-old infants across all three countries was 11.2% (95% confidence interval (CI) = 11.0-11.4). The DRC had the highest incidence of PSBI (19.0%; 95% CI = 18.2-19.8). Likewise, PSBI rates were higher in low birth weight infants (24.5%; 95% CI = 23.1-26.0) and infants born to mothers aged <20 years (14.1%; 95% CI = 13.4-14.8). The incidence of PSBI was higher among infants delivered at home (11.7%; 95% CI = 11.4-12.0).
Conclusions
UNASSIGNED
The high burden of PSBI among young infants in DRC, Kenya, and Nigeria demonstrates the importance of addressing PSBI in improving child survival in sub-Saharan Africa to reach the Sustainable Development Goals (SDGs). These data can support government authorities, policymakers, programme implementers, non-governmental organisations, and international partners in reducing preventable under-five deaths.
Registration
UNASSIGNED
Australian New Zealand Clinical Trials Registry: ACTRN12610000286044.
Identifiants
pubmed: 38299777
doi: 10.7189/jogh.14.04009
pmc: PMC10832543
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
04009Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
Copyright © 2024 by the Journal of Global Health. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and disclosed the following activities and/or relationships: YBN is a staff member of the World Health Organization. The expressed views and opinions do not necessarily express the policies of the World Health Organization.
Références
Arch Dis Child. 2021 Jan 22;:
pubmed: 33483376
Arch Dis Child Fetal Neonatal Ed. 2005 May;90(3):F220-4
pubmed: 15846011
PLoS One. 2022 Jun 13;17(6):e0269524
pubmed: 35696401
Pediatr Infect Dis J. 2009 Apr;28(4):304-10
pubmed: 19289979
PLoS One. 2021 Jul 7;16(7):e0252700
pubmed: 34234352
PLoS One. 2020 Dec 22;15(12):e0243724
pubmed: 33351810
Glob Health Res Policy. 2022 Jul 20;7(1):20
pubmed: 35854345
Pediatr Infect Dis J. 2013 Sep;32 Suppl 1:S26-32
pubmed: 23945572
Lancet. 2008 Jan 12;371(9607):135-42
pubmed: 18191685
PLoS One. 2020 Jun 4;15(6):e0234212
pubmed: 32497092
PLoS One. 2022 Jun 30;17(6):e0268277
pubmed: 35771738
Pediatr Infect Dis J. 2005 Apr;24(4):335-41
pubmed: 15818294
PLoS One. 2020 Apr 14;15(4):e0231490
pubmed: 32287286
J Public Health (Oxf). 2023 Mar 14;45(1):176-188
pubmed: 35138390
Lancet Infect Dis. 2014 Aug;14(8):731-741
pubmed: 24974250
Lancet. 2015 May 2;385(9979):1758-1766
pubmed: 25842223
J Health Popul Nutr. 2018 Mar 9;37(1):6
pubmed: 29523194
PLoS One. 2021 Aug 9;16(8):e0255210
pubmed: 34370744
Pediatr Neonatol. 2016 Aug;57(4):265-73
pubmed: 26750406
Pediatrics. 2005 Feb;115(2 Suppl):519-617
pubmed: 15866863
PLoS One. 2020 Aug 24;15(8):e0236355
pubmed: 32833993
PLoS One. 2020 Apr 14;15(4):e0229248
pubmed: 32287262
Lancet Glob Health. 2018 Dec;6(12):e1297-e1308
pubmed: 30361107
PLoS One. 2021 Mar 30;16(3):e0248720
pubmed: 33784321
Lancet. 2015 May 2;385(9979):1767-1776
pubmed: 25842221
Reprod Health. 2016 May 24;13(1):65
pubmed: 27221099
PLoS One. 2021 Feb 5;16(2):e0244192
pubmed: 33544712
Pediatr Res. 2023 Oct;94(4):1278-1283
pubmed: 37202529
Lancet Glob Health. 2017 Feb;5(2):e177-e185
pubmed: 27988146
BMC Public Health. 2015 Sep 30;15:989
pubmed: 26419934
PLoS One. 2020 May 11;15(5):e0232675
pubmed: 32392209
PLoS Med. 2010 Mar 09;7(3):e1000213
pubmed: 20231868
Lancet. 2005 Mar 26-Apr 1;365(9465):1175-88
pubmed: 15794973
PLoS One. 2020 Mar 10;15(3):e0228718
pubmed: 32155155
Lancet Glob Health. 2015 May;3(5):e279-87
pubmed: 25841891
BMC Pregnancy Childbirth. 2020 Nov 11;20(1):684
pubmed: 33176718